Similar to the ASH abstracts, each year the American Society for Haematologists publishes a series of articles that give an in-depth discussion of subjects of particular importance.
To access each item simply click on the book beside it.
2014
|
Diagnosis of ‘double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC |
|
Impact of MYC on malignant behavior |
|
Double-hit lymphomas: current paradigms and novel treatment approaches |
|
Indolent lymphoma: follicular lymphoma and the microenvironment—insights from the microscope |
|
Indolent lymphoma: follicular lymphoma and the microenvironment—insights from gene expression profiling |
|
Therapeutic targeting of microenvironment in follicular lymphoma |
|
Optimal disease surveillance strategies in non-Hodgkin lymphoma |
|
Caring for the long-term survivor after allogeneic stem cell transplantation |
|
Cytotoxic T lymphocytes for leukemia and lymphoma |
|
Maximizing GVL in allogeneic transplantation: role of donor lymphocyte infusions |
|
2013
|
Targeting B-cell receptor signaling: changing the paradigm |
|
Dissecting follicular lymphoma: high versus low risk |
|
Transplantation for mantle cell lymphoma: is it the right thing to do? |
|
Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification |
|
Treatment strategies for aggressive lymphomas: what works? |
|
Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP |
|
2012
|
Interim PET-CT in the management of diffuse large B-cell lymphoma |
|
Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma |
|
Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma? |
|
Changing role of stem cell transplantation in follicular lymphoma |
|
The many faces of marginal zone lymphoma |
|
Is there a role for “watch and wait” in follicular lymphoma in the rituximab era? |
|
2011
|
Allogeneic Immunotherapy to Optimize the Graft-versus-Tumor Effect: Concepts and Controversies |
|
B Cells Behaving Badly: A Better Basis to Behold Belligerence in B-Cell Lymphomas |
|
Tricky and Terrible T-Cell Tumors: These are Thrilling Times for Testing: Molecular Pathology of Peripheral T-Cell Lymphomas |
|
Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
|
Therapies for Peripheral T-Cell Lymphomas |
|
2010
|
Long-Term Physiological Side Effects After Allogeneic Bone Marrow Transplantation |
|
Comorbidities and Hematopoietic Cell Transplantation Outcomes |
|
Health-Related Quality of Life Following Allogeneic Hematopoietic Stem Cell Transplantation |
|
Host Factors for Risk and Survival in Lymphoma |
|
Novel Agents for Follicular Lymphoma |
|
2009
|
The 2008 WHO classification of lymphomas: implications for clinical practice and translational research |
|
The incidence, natural history, biology, and treatment of transformed lymphomas |
|
Current treatment standards and emerging strategies in mantle cell lymphoma |
|
2008
|
Marginal Zone Lymphomas: Management of Nodal, Splenic, and MALT NHL |
|
Primary Mediastinal B-Cell Lymphoma |
|
Burkitt Lymphoma in Adults |
|
Novel Therapies and Role of Transplant in the Treatment of Peripheral T-Cell Lymphomas |
|
Prognosis and Primary Therapy in Peripheral T-Cell Lymphomas |
|
Pathobiology and Molecular Profiling of Peripheral T-Cell Lymphomas |
|
Recognizing and Managing Chronic Graft-Versus-Host Disease |
|
Old and New Cancers after Hematopoietic-Cell Transplantation |
|
Does High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation Have a Role in the Primary Treatment of Peripheral T-Cell Lymphomas? |
|